Novo Nordisk Background

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy righ

Seeking Alpha · 2d

Novo Nordisk: Stock Plunges, But It May Be Time To Load Up

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.

Business Insider · 3d

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 3d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Seeking Alpha on MSN · 3d

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) ended a five-day losing streak on Thursday after Kepler Cheuvreux, a long-time skeptic of the Danish biotech, finally issued a bullish rating on the maker of hugely popular obesity/ diabetes drugs,

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Fox Business6d

Novo Nordisk shares fall on weight-loss drug trial

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

The Washington Post12d

Novo Nordisk slashes Wegovy price for patients lacking insurance benefits

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk: CagriSema Disappoints Again

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

New York Post11d

Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results